Dr. An currently leads clinical drug development activities as Chief Medical Officer. Previously, Dr. An served as assistant professor at Pediatric Hematology and Oncology department of Seoul National University Hospital.



  • PhD Candidate, Translational Medicine, Department of Medicine, Seoul National University, Korea
    Medical Doctor, Seoul National University College of Medicine, Korea
  • Board of Pediatrics, Critical Care Medicine, Pediatric Hematology and Oncology, Pediatric Emergency Medicine, Korea



  • 30+ publications (Blood, Bone marrow transplantation, PNAS, Pediatric hematology and oncology etc.)



Conducted 30+ clinical trials

  • Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
  • Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
  • Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
  • Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors (SCOUT)
  • A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma (FIREFLY-1)

Hongyul An, MD / PHD Candidate

Chief Medical Officer